非小细胞肺癌免疫治疗疗效预测的研究进展

近年来，免疫检查点抑制剂(immune checkpoint inhibitors,ICI)治疗晚期非小细胞肺癌进入了一个新纪元，但不同于靶向治疗，免疫治疗没有明确的疗效预测因子以指导临床。目前应用较多的是程序性死亡受体配体(programmed cell death ligand 1,PD-L1)表达的检测，然而多项临床试验结果提示只有约20%的NSCLC患者能从中获益。而肿瘤突变负荷(tumor mutation burden,TMB)也逐渐兴起，还有许多检测因子尚在发现中。本综述旨在探讨非小细胞肺癌中免疫治疗的疗效预测因子以更好地指导临床。

Progress of immunotherapy prognostic factors in non-small cell lung cancer

Immune checkpoint inhibitors(ICI)have been successfully used in the patients with advanced non-small cell lung cancer(NSCLC).But,the immunotherapy still lacks perfect biomarkers for guiding the clinic.Currently,programmed cell death ligand 1(PD-L1)expression detecting by immune histochemistry(IHC)is the most common used predictive marker for ICI.Many clinical trials have showed that only about 20%of NSCLC patients can benefit from this immunotherapy,and the tumor mutation burden(TMB)is an emerging biomarker,meanwhile,many biomarkers are reaching.This review describes the some factors of curative effect to provide a reference for further clinical application.